Stereotaxis raises up to $24M convertible notes at $1.21; Q3 revenue $8.9M up 20% YoY

Stereotaxis, Inc.

Convertible note financing of up to $24.0M: $12.0M closed Nov. 9, 2026, plus up to $12.0M at Stereotaxis' option subject to regulatory milestones; 10% annual interest, three-year maturity.
Notes convert at $1.21/share, a 30% premium to the 10-day VWAP; interest is deferred and paid in kind at maturity; board-affiliated investors participated in the oversubscribed deal.
Q3 2026 revenue $8.9M, up 20% YoY; system revenue $3.0M vs $1.9M on first US GenesisX, first China Genesis and Synchrony sales; recurring revenue $5.9M, up 6%.
Q3 net loss $6.5M; adjusted operating loss $5.1M vs $2.5M, reflecting Robocath costs; adjusted opex guided to ~$8M/quarter, targeting cash-flow profitability within a year.
Cash was $4.0M at Sept. 30; pro forma $16M after the $12M initial close, with $28M total availability; $1.9M disposable backlog delayed by supply constraints.

item 1.01 item 2.02 item 2.03 item 3.02 item 9.01

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.